hit counter joomla

@finchtalk

About Todd Smith: I co-founded Geospiza, Inc. and served in several executive roles until its acquisition by PerkinElmer (PKI) in 2011, where I continued to develop genomics strategies and products until 2013.

I have broad technical and market knowledge with depth in the areas of bioinformatics, genomics, systems biology, and software systems with a clinical and diagnostic focus. Presently, I provide business and technical consulting services through Digital World Biology to help organizations develop genetic analysis strategies and technical implementation plans.

Prior to Geospiza, I was postdoctoral scientist in Dr. Leroy Hood’s laboratory and sequenced the BRCA1 gene with Mary-Claire King. My peer reviewed and invited publications are in human genetics, microbiology, chemistry, computer science and education. I hold a Ph.D. in Medicinal Chemistry from University of Washington and B.S. degrees Genetics and Biochemistry from University of Minnesota.

In our series on why $1000 genomes cost $2000, I raised the issue that the $1000 genome is a value based on simplistic calculations that do not account for the costs of confirming the results. Next, I discussed how errors are a natural occurrence of the many processing steps required to sequence DNA and why…

Could you repeat that please?

Previously, I introduced the idea that the $1000 genome has not been achieved because it is defined in simplistic terms that ignore many aspects of data completeness and verification. In that analysis, I cited a recent perspective by Robasky, Lewis, and Church [1] to present concepts related to the need to verify results and the…

$1000 Genomes for $2000

Getting an accurate genome sequence requires that you collect the data at least twice argue Robasky, Lewis, and Church in their recent opinion piece in Nat. Rev. Genetics [1]. The DNA sequencing world kicked off 2014 with an audacious start. Andrew Pollack ran an article in the New York Times implying that 100,000 genomes will…